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Abstract Somatic gene copy number variation con-
tributes to tumor progression. Using comparative genomic
hybridization (CGH) array, the presence of genomic im-
balances was evaluated in a series of 27 papillary thyroid
carcinomas (PTCs). To detect only somatic imbalances, for
each sample, the reference DNA was from normal thyroid
tissue of the same patient. The presence of the BRAF
V600E mutation was also evaluated. Both amplifications
and deletions showed an uneven distribution along the
entire PTC cohort; amplifications were more frequent than
deletions (mean values of 17.5 and 7.2, respectively).
Number of aberration events was not even among samples,
the majority of them occurring only in a small fraction of
PTCs. Most frequent amplifications were detected at re-
gions 2q35, 4q26, and 4q34.1, containing FN1, PDE5A,
and GALNTL6 genes, respectively. Most frequent deletions
occurred at regions 6q25.2, containing OPMR1 and
IPCEF1 genes and 7q14.2, containing AOAH and ELMO1
genes. Amplification of FN1 and PDE5A genomic regions
was confirmed by quantitative PCR. Frequency of
amplifications and deletions was in relationship with clin-
ical features and BRAF mutation status of tumor. In fact,
according to the American Joint Committee on Cancer
stage and American Thyroid Association (ATA) risk
classification, amplifications are more frequent in higher
risk samples, while deletions tend to prevail in the lower
risk tumors. Analysis of single aberrations according to the
ATA risk grouping shows that amplifications containing
PDE5A, GALNTL6, DHRS3, and DOCK9 genes are sig-
nificantly more frequent in the intermediate/high risk group
than in the low risk group. Thus, our data would indicate
that analysis of somatic genome aberrations by CGH array
can be useful to identify additional prognostic variables.
Keywords CGH array  Somatic mutation  Papillary
thyroid carcinoma
Introduction
Identification of molecular mechanisms and markers of
tumor progression and aggressiveness is a central theme in
cancer research. Papillary thyroid carcinoma (PTC) repre-
sents the most frequent form (80–85 %) of thyroid malig-
nancy [1]. Most PTCs are biologically indolent and have a
very good prognosis (survival rates of 90–95 % at 5 years),
thanks to their responsiveness to radioiodine treatment [2].
However, 5–10 % PTCs show a more aggressive behavior
and a worse prognosis [3]. Knowledge of the molecular
mechanisms that contribute to aggressiveness of PTCs is
critical to propose tailored therapy approaches. Genetic and
epigenetic alterations are both involved in the pathogenesis
and progression of thyroid tumors [4–6]. Several studies
indicate that the most common genetic alteration found in
PTC is the V600E mutation of the BRAF gene [7]. Many
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studies indicate that the presence of this BRAF mutation in
PTCs is associated to poor clinicopathological outcomes,
including aggressive pathological features, increased re-
currence and treatment failure [4, 8, 9]. Gene copy number
variation may also contribute to PTC progression. In par-
ticular, gene amplification has been shown to be related to
tumor aggressiveness [10, 11]. An efficient way to evaluate
the presence of copy number variation at genomic levels is
the comparative genomic hybridization (CGH) array [12].
In this microarray technology, gene dosage of a test gen-
ome is compared to that of a reference genome, and im-
balance due to deletions or amplifications of genomic
regions is easily detected. CGH array has been extensively
used for the identification of genomic imbalances present
in cancer [13]. Several data come from studies on thyroid
tumors [14–16]. In most of them, however, the reference
genome used in the CGH array was not that of the same
patient. In this way, somatic copy number variations that
occur in tumor cells (and that may have a role in tumor
progression) cannot be distinguished from germline copy
number variations existing in distinct human genomes [17].
The present study was conducted to identify copy
number variations in PTCs by CGH array. In addition, we
confirmed CGH array data by quantitative real-time PCR
of selected genes and evaluated the presence of BRAF
V600E mutation. Correlation analyses were performed
with clinical/pathological characteristics according to the
American Joint Committee on Cancer/Tumor Nodes Me-
tastasis (AJCC/TNM) staging of tumors and the 2009
American Thyroid Association (ATA) initial risk stratifi-
cation system, in order to find new genetic markers for
prognostic predictions.
Materials and methods
Patients
For CGH array analysis, 27 subjects (23 females and 4
males) affected by PTC were examined. The mean age
was 45 ± 10 (range 17–74) years. Thyroid tissues were
obtained at thyroidectomy; for each subject, both tumor
and non-tumor (normal) thyroid tissues were available.
All samples were diagnosed by referral pathologists of
the institutions and then reviewed by a single experi-
enced pathologist, thus including only tumors with con-
firmed diagnosis. The study was approved by the medical
ethics committee of the Azienda Ospedaliero-Universi-
taria S. Maria della Misericordia of Udine. Before sur-
gery, each study participant provided written informed
consent to the collection of thyroid tissue for genetic
studies.
DNA extraction from thyroid tissues
For each patient, we used tumor and non-tumor tissue
samples. From each tissue sample, formalin-fixed paraffin-
embedded (FFPE) specimens were cut in 10-lm-thick
sections on a microtome; one section treated with hema-
toxylin–eosin staining was used for histological confirma-
tion of the presence of tumor cells, and the tumor area was
highlighted by pathologist. Non-tumor tissue samples were
controlled by the pathologist to completely exclude the
presence of tumor cells. Genomic DNA was isolated from
the FFPE specimens using NucleoSpin Tissue Kit
(Macherey–Nagel, Du¨ren, Germany) following manufac-
turer’s instructions. Extracted DNA was quantified using a
NanoDrop 2000 spectrophotometer (Thermo Scientific,
Waltham, MA, USA).
Evaluation of the BRAF V600E mutation
100 ng of isolated DNA was amplified by polymerase
chain reaction (PCR) using 200 lM dNTPs, 1.5 mM
MgCl2, 1 U of AmpliTaq Gold, and Buffer 19 AmpliTaq
Gold DNA Polymerase (Applied Biosystems/Life tech-
nologies Italia, Monza, Italy). The PCR was carried out
using 10 pmol of specific primers for exon 15 of the BRAF
gene: (Forward): TCATAATGCTTGCTCTGATAGGA,
(Reverse): GGCCAAAAATTTAATCAGTGG. The cy-
cling condition for PCR program was 95 C for 10 min,
followed by 40 cycles of 95 C for 1 min, 60 C for 1 min,
and 72 C for 1 min. A final 7 min extension was included
at the end of 40 cycles. The reactions were performed in a
Veriti 96-well Thermal Cycler (Applied Biosystems/Life
technologies Italia). PCR products were subjected to 1.5 %
agarose gel electrophoresis with ethidium bromide staining
and purified with a commercial kit (NucleoSpin Gel and
PCR Clean-up, from Macherey–Nagel).
All PCR products were sequenced using Big DyeTM
Terminator version 3.1 Cycle sequencing kit (Applied
Biosystems/Life technologies Italia), and one of the pri-
mers previously described was used for amplification. The
sequencing reaction was carried out for 25 cycles (de-
naturation for 10 s at 96 C, annealing for 5 s at 50 C, and
elongation for 4 min at 60 C). The products of this reac-
tion were purified using NucleoSeq Column (Macherey–
Nagel) and subjected to capillary gel electrophoresis. Data
collection and analysis were performed on an Applied
Biosystems 3130xl automated sequencer (Applied
Biosystems/Life technologies Italia). All PCR reactions
and sequencing were repeated at least twice to confirm the
presence of a mutation. This procedure allows to detect as
low as 10 % mutated alleles, in agreement with most recent
data [18].
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CGH array
Because salt from Buffer B5 (NucleoSpin Tissue Kit,
Macherey–Nagel) interferes with the labeling reaction,
DNA was purified by precipitation with 1/10 vol of 0.3 M
sodium acetate and 3 vol of ice-cold ethanol. The pellet
obtained after centrifugation was washed with 1 vol of ice-
cold 70 % ethanol and resuspended in nuclease free H2O.
CGH array experiments were performed using SurePrint
G3 Human CGH Microarray 4 9 180 K cat n. G4449A
(Agilent Technologies, Santa Clara, CA, USA) according
to the manufacturer’s instructions. Each array consists of
170,000 in situ synthesized 60 mer oligonucleotide probes
that span coding and non coding sequences with an average
spatial resolution of 13 kb.
To label DNA samples the one-step non-enzymatic
Agilent Genomic DNA ULS labeling kit (Agilent Tech-
nologies) according to the ULS Labeling for Blood, Cells,
Tissue, or FFPE (with a high throughput option) protocol
v. 3.3 was utilized. As reference DNA for each sample,
DNA extracted from non-tumor tissue of the same patient
was used. 500 ng of sample DNA (tumor tissue) and
500 ng of reference DNA (non-tumor tissue) were labeled
with ULS-Cy5 and ULS-Cy3, respectively. The degree of
labeling was calculated using the Nanodrop ND 1000
Spectrophotometer (Thermo Scientific). The differentially
labeled DNA samples were hybridized (65 C) to the
microarray for 40 h in a hybridization oven (Agilent
Technologies). The slides, during hybridization, were
rotated at 20 rpm. The array was scanned at 3 lm resolu-
tion using Agilent microarray scanner and analyzed using
Feature Extraction v. 10.7.1.1 and FE Protocol CGH_107_
Sept09 (Agilent Technologies).
CGH array data analysis
Copy number analysis was performed using the analytic
module of Agilent Genomic Workbench Lite Edition
6.5.018 software (Agilent Technologies). The array CGH
data are assessed with a series of quality control (QC)
metrics then analyzed using the Aberration detection al-
gorithm ADM2. The latter identifies all aberrant intervals
in a given sample with consistently high or low log ratios,
based on the statistical score derived from the average
normalized log ratios of all probes in the genomic interval
multiplied by the square root of the number of these
probes. This score represents the deviation of the average
of the normalized log ratios from its expected value of zero
and is proportional to the height h (absolute average log
ratio) of the genomic interval and to the square root of the
number of probes in the interval. The ADM2 algorithm
prompted by Genomic Workbench software was used to
compute and assist the identification of aberrations for a
given sample (threshold = 6.0), and detected regions were
filtered for those spanning more than three consecutive
probes with an average absolute log2 ratio[0.45 [19, 20].
The minimum average spatial resolution consists of 40 kb.
Statistical analysis
To identify genomic intervals that have statistically sig-
nificant common aberrations was used the ‘‘context cor-
rected’’ common aberration analysis (Agilent Genomic
Workbench Lite Edition 6.5.018 software, p value thresh-
old = 0.05, Overlap threshold = 0.1). This method adjusts
the significance of a genomic interval according to the
overall aberration state of the sample.
In order to evaluate correlation of genetic aberration
detected by CGH array with AJCC staging, ATA risk, and
BRAF mutational status, statistical analysis was performed
by the t test using the Graphpad software. Values of
p\ 0.05 were considered statistical significant.
Quantitation of FN1 and PDE5A gene dosage
by PCR
Five nano gram of DNA was amplified by real-time PCR
(RT-PCR) reaction using buffer 19 Platinum SYBR Green
qPCR SuperMix-UDG with ROX (Applied Biosystems/
Life Technologies Italia). The RT-PCR was carried out
using 3.75 pmol of the following specific primers: for FN1
gene (Forward): CCGAGGAGAGTGGAAGTGTGA,
(Reverse): GAAAGATGGATTTGCGGAAATATT; for
PDE5A gene (Forward): TTGGAGGTGGGTGAAGTT
TAGG, (Reverse): TGAGTGATTATGAGGGAAAGG
TAAAA; for ALB gene (used as a reference) (Forward):
ATGCTGCACAGAATCCTTGGT, (Reverse): TCATC
GACTTCCAGAGCTGAAA. The cycling condition for
RT-PCR program was 50 C for 2 min, 95 C for 10 min,
followed by 40 cycles of 95 C for 15 s, 60 C for 1 min.
The reactions were performed in a ABI Prism 7300
Sequence Detection System (Applied Biosystems/Life
Technologies Italia). The 2-DDCT (cycle threshold) method,
by means of the SDS software (Applied Biosystems/Life
Technologies Italia), was used to calculate the relative gene
quantity [21]. The relative gene target quantity of each
tumor sample was normalized to its healthy counterpart
(calibrator), which has arbitrarily considered as 1.
Results
Clinicopathological features of investigated patients are
shown in Table 1. Using CGH array, each tumor sample
was compared to the normal genome of the same subject
(from non-tumor thyroid tissue), thus only somatic
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mutations were identified. Examples of CGH array profiles
are shown in supplemental Figs. 1 and 2. Multiple genomic
imbalances were detected in all tumors. In terms of mean
number of imbalances, though not reaching a statistical
significance, a prevalence of amplifications over deletions
was observed with mean values of 17.5 and 7.2 for am-
plifications and deletions, respectively (Fig. 1a). Panel b of
Fig. 1 shows the percentage of imbalances of different
length. As expected, short deletions/amplifications are
prevailing: around 70 % of imbalances are below 200 kb.
The distribution of aberrations was extremely uneven
among the entire cohort of PTCs. As shown in panel a of
Fig. 2, the fraction of amplification events is not even, the
majority of them occurring only in a fraction of PTCs.
About 25 % of top-ranking samples (7 cases) contained the
75 % of amplifications. A similar scenario was observed
for deletions: the 25 % of top-ranking samples (5 cases)
contained the 75 % of deletions (Fig. 2b).
Patients’ tumors are grouped by AJCC stage, ATA risk,
and BRAF mutational status (Table 1). We tested whether
amplifications and deletions were differently distributed
according to these criteria, and statistical significance was
determined by the Student’s t test. As shown in Fig. 3, for
the AJCC stage, amplifications were not significantly more
prevalent in stage III-IV group than in stage I group (p:
0731), and the reverse phenomenon was detected for
deletions (p: 0.249). Significant differences were detected
between the ATA risk groups: amplifications were more
prevalent in intermediate/high risk group than in low risk
group (p: 0.046), while deletions were more prevalent in
Table 1 Characteristics of the study population
N. Sex/age in years T N M Histological variant AJCC stagea ATA riskb BRAF status
1 f/45 T1a N0 M0 C I Low WT
2 f/74 T1a N0 M0 FV I Low WT
3 f/26 T1b N0 M0 C I Low WT
4 f/56 T1a N0 M0 ST I Low WT
5 f/61 T1a N0 M0 ST I Low WT
6 f/47 T1a N0 M0 C I Low WT
7 f/56 T1a N0 M0 ST I Low WT
8 f/43 T1a N0 M0 C I Low WT
9 f/40 T1a N0 M0 C I Low WT
10 f/31 T1b(m) N0 M0 C I Low WT
11 f/19 T1b N1b M0 FV I Intermediate WT
12 f/46 T3(m) N0 M0 C III Intermediate WT
13 f/56 T3 N0 M0 FV III Intermediate WT
14 f/47 T3 N0 M0 C III Intermediate WT
15 f/44 T3 N1b M0 C III Intermediate WT
16 m/54 T3(m) N1b M0 C IVa Intermediate WT
17 f/46 T2 N1b M0 FV IVa Intermediate WT
18 f/17 T3 N1b M0 C IVa Intermediate WT
19 m/35 T1b(m) N1b M0 C I Intermediate V600E
20 f/42 T1a N1a M0 C I Intermediate V600E
21 m/36 T3 N1a M0 C I Intermediate V600E
22 f/43 T1a N1a Mx C I Intermediate V600E
23 f/33 T1b(m) N1a Mx C I Intermediate V600E
24 f/42 T1b N1 Mx C I Intermediate V600E
25 m/61 T3(m) N1b M0 C IVa Intermediate V600E
26 f/55 T3 N1b M0 FV IVa Intermediate V600E
27 f/59 T3(m) N0 M1 FV IVc High WT
T tumor, N node, M metastasis, C classic, FV follicular variant, ST sclerosing type, AJCC American Joint Committee on Cancer, ATA American
Thyroid Association, f female, m male, WT wild-type
a TNM AJCC/UICC staging system, 7th edition, 2010
b American Thyroid Association risk stratification staging system
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low risk group than in intermediate/high risk group (p:
0.049). No significant differences were detected between
groups harboring or not the BRAF V600E mutation, even if
amplifications were more prevalent in mutant group (p:
0.446) and deletions more prevalent in the wild-type group
(p: 0.247).
Then, our attention was focused on recurrent aberra-
tions: we decided to define as recurrent aberrations those
deletions or amplifications present in at least 5 samples of
the whole cohort. Using this cut-off value, 30 aberrations
were judged as recurrent, 23 aberrations were judged as
amplifications, and 7 aberrations were judged as deletions
(this difference is statistically significant according to the
two-tailed binomial test; p = 0.0052). In Fig. 4, location of
recurrent amplifications and deletions along chromosomes
is depicted. Mean values of recurrent amplifications and
deletions grouped according to the AJCC stage, ATA risk,
and BRAF mutational status are shown in Fig. 5. Statistical
significance was obtained for the ATA risk grouping, in
which amplifications were more prevalent in intermediate/
high risk than in low risk group (p: 0.033) and for the
BRAF mutational status, in which amplification was more
prevalent in the mutant group than in the wild-type group
(p: 0.040). Table 2 shows locations, largeness as well as
the number of samples containing recurrent aberrations.
Most frequent amplifications occurred at regions 2q35 (in
15 samples), 4q26 (in 12 samples), and 4q34.1 (in 11
samples). Most frequent deletions occurred at regions
6q25.2 and 7q14.2 (both present in 7 samples). The dele-
tion at 7q14.2 was the largest aberration (almost one
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Fig. 2 Distribution of genomic aberrations in PTCs. aAmplifications;
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megabase). The data of recurrent aberrations in the PTCs
divided into subgroups according to AJCC stage, ATA risk,
or BRAF mutational status are presented in Table 2. In the
ATA risk grouping, amplifications at locations 1p36.22,
4q26, 4q34.1, and 13q32.3 were significantly more fre-
quent in the intermediate/high risk group than in low risk
group. According to the BRAF mutational status, deletions
at locations 6q11.1 and 6q25.2 were more frequent in the
wild-type group than in the samples bearing the V600E
mutations. In order to confirm the CGH array data, dosage
of two genes present in recurrent amplifications at chro-
mosomes 2q35 and 4q26 (FN1 and PDE5A) was performed
by quantitative PCR. These two genes were chosen for a
potential functional role in thyroid tumorigenesis (see
‘‘Discussion’’ section). Thirteen samples with amplification
of region containing FN1 gene and nine samples with
amplification containing PDE5A gene have been evaluated.
As shown in Fig. 6, tumor tissues in which amplification
has been detected by array CGH showed significant higher
relative quantity of both FN1 and PDE5A genes than cor-
responding normal tissues. Moreover, tumors in which no
amplification has been detected by array CGH showed
relative quantity similar to control tissues. These data
confirm that genomic regions containing FN1 and PDE5A
genes are amplified in several thyroid cancer tissues.
Discussion
For several cancer types, genome-wide analysis by CGH
array has provided an extensive high-resolution delineation
of copy number changes present in tumor cells, adding
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important information on the genomic alterations occurring
during cancer progression [22]. In this work, we have
identified recurrent deletions and amplifications occurring
in the genome of PTCs, also delineating differences among
tumors divided according to the AJCC stage, ATA risk
classification, and BRAF mutational status. Molecular
karyotyping has been already used to study thyroid cancer.
However, early CGH investigations were performed using
metaphase chromosome spreads as detection system [23–
28]; thus, the resolution power of this approach was ex-
tremely limited. More recently, microarray has been used
as detection system. Most investigations, however, have
been performed using BAC or cDNA microarrays [29–31],
which still have a reduced power to detect genome im-
balances, because arrays contain from few hundreds to few
thousands immobilized probes. Oligonucleotide microar-
rays have been used to investigate thyroid cancer in one
study only [32]. In that study, microarrays contained
33.000 probes (33 K) and had an average resolution power
of 100 kb. Our study was performed by 180 K microarrays
and, therefore, has the highest resolution power. A second
major strong point of our investigation is the use of
genomic DNA from the same patient as reference DNA. In
this way, it has been possible to compare the tumor genome
to the normal genome for each patient and, therefore, focus
on somatic aberrations.
Using this approach, a major trend was overall observed,
that is the prevalence, in our series of PTCs, of amplifi-
cations versus deletions. Prevalence of genomic gains with
respect to losses has been previously observed in other
neoplasms. For example, Sandgren and coworkers by in-
vestigating pheochromocytomas and paragangliomas have
shown that genome gains were more frequent in malignant
than benign tumors [33]. In contrast, in the case of PTCs,
Unger et al. have shown higher frequency of deletions than
amplifications [30], whereas Finn et al. have shown no
significant predominance of one versus the other [29].
An integrated genomic characterization of PTC has been
recently published [34]. In that study, to the identification
of somatic copy number alterations, SNP array was infor-
mative in 495 PTCs. Only 135 of them (27.2 %) were
positive for somatic aberrations. Thus, most tumors were
considered negative for deletions/amplifications, four dis-
tinct classes were defined, and two of them were
Fig. 4 Recurrent amplifications/deletions in PTCs. Filled circles flanking chromosome ideograms indicate presence of amplifications or
deletions. Circles on the right of each ideogram indicate amplifications, while symbols on the left indicate deletions
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characterized for either 22q deletions or 1q amplifications.
Instead, in our study, we have found copy number alter-
ations in most PTCs. In addition, we have found a recurrent
amplification in the 1q region, but not recurrent deletions
were observed in the 22q region. Differences between our
study and that of the TCGA Research Network likely arise
from methodology. Besides technological differences, it is
important to point out that the TCGA Research Network
focused on chromosomal arm-level alterations, i.e., dele-
tions or amplifications that comprise at least the 66 % of
the chromosomal arm. Therefore, in that research authors
focused on very large inbalances, while we analyzed also
relatively small aberrations (40 kb is the minimal aberra-
tion length detection).
In our cohort of tumors, amplifications involving regions
2q35, 4q26, and 4q34.1 containing, respectively, FN1,
PDE5A, and GALNTL6 genes resulted the most frequent
(Table 2). FN1 encodes for fibronectin, an extracellular
matrix glycoprotein that binds to integrins expressed in the
cell membrane and plays a major role in migration, growth,
cell adhesion, and differentiation [35]. Several studies have
demonstrated that fibronectin degradation or its altered
expression and organization are associated with a number
of pathologies, including fibrosis and cancer [36]. Inter-
estingly, a significant overexpression of FN1 mRNA has
been reported in PTCs [37], as well as amplification of its
genomic region [26]. Therefore, this gene has been pro-
posed as a molecular marker of differentiated thyroid car-
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cinomas, usable for discrimination between benign or not
follicular thyroid tumors [38, 39]. On the other side,
PDE5A belongs to the family of phosphodiesterase en-
zymes, which act hydrolyzing adenosine and guanosine
30,50-cyclic monophosphates (cAMP and cGMP) and
therefore influencing the nucleotide signaling pathway [40,
41]. In particular, the PDE5A isoform is able to specifically
hydrolyze cGMP, a second messenger acting as regulator
of various physiological processes in many tissues, in-
cluding thyroid [40, 41]. Expression of PDE5A has been
demonstrated in normal thyroid tissue [42], where cGMP
mediates inhibition of different steps of thyroid hormone
biosynthesis [43], and very recent findings of our group
have demonstrated an overexpression of both PDE5 mRNA
and protein in a large series of PTCs [Sponziello et al.
unpublished observations] GALNTL6 gene codes for N-
acetylgalactosaminyltransferase-like 6 protein; no data are
available on its expression in malignancies.
Difference in the distribution of amplifications and
deletions was observed also when the tumors were ana-
lyzed according to the AJCC stage and ATA risk classi-
fication. In general, advanced TNM stages and
intermediate/high risk status are considered predictors of a
higher risk of disease mortality and disease persistence/
recurrence, respectively, although these risk estimates
may change overtime according to the clinical course of
Table 2 Recurrent amplifications and deletions present in PTCs
Chr Size (bp) Amp/del Involved genes Number of samples AJCC stage ATA risk BRAF status
I III IV Low Inter WT MUT
1p36.22 49547 Amp DHRS3 6 3 3 0 6 1 5
1p36.12 75880 Amp ECE1 5 3 2 0 5 2 3
1q21.3 32706 Amp CTSS 6 3 3 1 5 3 3
2q24.2 28845 Amp DPP4 5 2 3 0 5 2 3
2q35 73249 Amp FN1 15 9 6 4 11 8 7
2q37.3 30131 Amp PASK 5 2 3 1 4 5 0
3p14.1 82722 Amp ADAMTS9 9 5 4 2 7 7 2
3q27.2 322848 Amp LIPH/SENP2/IGFBP2 6 3 3 1 5 3 3
3q29 100443 Amp ATP13A4 5 2 3 0 5 2 3
4q26 115181 Amp PDE5A 12 7 5 2 10 6 6
4q34.1 83183 Amp GALNTL6 11 5 6 1 10 6 5
4q35.1 145935 Del SORBS2 6 4 2 3 3 5 1
5q34 283907 Amp GABRB2 5 4 1 2 3 2 3
6q11.1 425097 Del KHDRBS2 6 3 3 2 4 6 0
6q25.2 114729 Del OPMR1/IPCEF1 7 5 2 4 3 7 0
7q14.2 931162 Del AOAH/ELMO1 7 4 3 3 4 6 1
7q21.11 264493 Del SEMA3D 6 2 4 1 5 5 1
9q21.32 273206 Amp FRMD3 8 5 3 2 6 5 3
11p14.1 352999 Del MPPED2 6 3 3 2 4 5 1
11p11.2 51679 Amp LRP4 8 6 2 3 5 6 2
12p12.3 183698 Amp EPS8 8 4 4 1 7 4 4
12p12.3 23645 Amp LMO3 5 3 2 0 5 2 3
13q32.3 289875 Amp DOCK9 9 6 3 1 8 3 6
15q21.3 348844 Del WDR72 5 4 1 3 2 5 0
15q21.3 81145 Amp RAB27A 6 3 3 1 5 3 3
17q23.2 109682 Amp MED13 5 3 2 0 5 1 4
Xp11.3 14809 Amp Unknown 7 4 3 1 6 3 4
Xp11.22 207793 Amp SHROOM4 5 4 1 2 3 4 1
Xq13.2 184323 Amp MIR374AHG 5 4 1 0 5 0 5
Xq25 850690 Amp ODZ1 9 4 5 2 7 7 2
Chr chromosome, Amp amplification, Del deletion, Inter intermediate. Italics are numbers that show a statistical significant difference (p\ 0.05)
according to the two-tailed binomial test
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the disease and the response to therapy. In this series of
PTCs, amplifications tend to be more frequent in higher
risk samples, while deletions tend to be prevailing in the
lower risk ones. A similar trend was observed also when
only recurrent aberrations were considered. In our ana-
lysis, we considered recurrent mutations those present in
at least 5 cases. Such a cut-off is roughly the same used
in many other studies, in which recurrent mutations are
defined those having a frequency equal or above 20 %
[33, 44–46]. When the analysis was performed at the
level of single aberrations, according to the ATA risk
grouping, amplifications containing PDE5A, GALNTL6,
DHRS3, and DOCK9 genes were significantly more fre-
quent in the intermediate/high risk group than in the low
risk group. DHRS3 (dehydrogenase/reductase (SDR
family) member 3 or retSDR1) catalyzes the oxidation/
reduction of a wide range of substrates, including reti-
noids and steroids [47], and is involved in a growth/tumor
suppressive pathway [48]. DHRS3 is constitutively ex-
pressed in breast cancer cell lines, and alterations of
DHRS3 have been described in metastatic PTCs, sug-
gesting a role in PTC pathogenesis and progression, and,
for this reason, is considered a possible molecular target
for PTC therapy [49]. DOCK9 codes for a member of
Dedicator of cytokinesis protein family involved in de-
velopment [50]; however, no data are available for these
proteins in thyroid tumorigenesis.
Finally, in our study, the results of genomic aberrations
have been correlated with the presence or not of BRAF
V600E mutation in the PTCs. In most studies, the BRAF
V600E mutation is associated to PTC aggressiveness [51–
53], owing to its association with several genetic and epi-
genetic damages observed in thyroid cancer cells [54, 55].
In general, amplifications in tumors with the BRAF V600E
mutation are more frequent than in those without this point
mutation, in agreement with the previous data in the more
aggressive subgroups. However, the single aberrations
detected with the highest difference between the two sub-
groups were the deletions in 6q chromosome corresponding
to KHDRBS2 and OPMR1 genes, found in wild-type
BRAF subgroup. For both genes, there are no evidences of
a functional role in either normal or transformed thyrocytes
[56–58].
In conclusion, our bona fide analysis of the somatic
genomic aberrations occurring in PTCs revealed a number
of amplifications/deletions, resulting presumably in altered
gene expression (as demonstrated for those containing the
FN1 and PDE5A genes), which characterize the tumor
genotype and may contribute to the tumor development.
Moreover, the finding of a higher frequency of particular
aberrations in subgroups with higher AJCC stage and ATA
risk level suggests that analysis of somatic genome aber-
rations by CGH array can be also useful to identify po-
tential prognostic variables.
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